ES2176206T3 - Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos. - Google Patents

Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos.

Info

Publication number
ES2176206T3
ES2176206T3 ES93918302T ES93918302T ES2176206T3 ES 2176206 T3 ES2176206 T3 ES 2176206T3 ES 93918302 T ES93918302 T ES 93918302T ES 93918302 T ES93918302 T ES 93918302T ES 2176206 T3 ES2176206 T3 ES 2176206T3
Authority
ES
Spain
Prior art keywords
derivatives
cyclodextrines
themselves
water
increased solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918302T
Other languages
English (en)
Other versions
ES2176206T5 (es
Inventor
Valentino J Stella
Roger Rajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25440795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176206(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Kansas filed Critical University of Kansas
Publication of ES2176206T3 publication Critical patent/ES2176206T3/es
Application granted granted Critical
Publication of ES2176206T5 publication Critical patent/ES2176206T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCUBREN LOS DERIVADOS DE CICLODEXTRINA ETER SULFOALQUIL Y SU USO COMO AGENTES SOLUBILIZADORES PARA MEDICAMENTOS INSOLUBLES EN AGUA PARA ADMINISTRACION ORAL, INTRANASAL O PARENTERAL.
ES93918302T 1992-07-27 1993-07-26 Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos. Expired - Lifetime ES2176206T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US918702 1992-07-27
US07/918,702 US5376645A (en) 1990-01-23 1992-07-27 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Publications (2)

Publication Number Publication Date
ES2176206T3 true ES2176206T3 (es) 2002-12-01
ES2176206T5 ES2176206T5 (es) 2008-12-01

Family

ID=25440795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93918302T Expired - Lifetime ES2176206T5 (es) 1992-07-27 1993-07-26 Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos.

Country Status (16)

Country Link
US (1) US5376645A (es)
EP (1) EP0620828B2 (es)
JP (1) JP3393253B2 (es)
KR (1) KR100279111B1 (es)
AT (1) ATE217325T1 (es)
AU (1) AU672814B2 (es)
CA (1) CA2119154C (es)
DE (1) DE69331900T3 (es)
DK (1) DK0620828T4 (es)
ES (1) ES2176206T5 (es)
GE (1) GEP19991649B (es)
MD (1) MD1813C2 (es)
PT (1) PT620828E (es)
RU (1) RU2113442C1 (es)
TJ (1) TJ275B (es)
WO (1) WO1994002518A1 (es)

Families Citing this family (615)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
DK0877600T3 (da) * 1996-08-09 2004-02-02 Alcon Mfg Ltd Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
RU2173172C2 (ru) * 1997-05-05 2001-09-10 Сайдекс Инк. Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
JP4439596B2 (ja) * 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク． 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
CA2306465A1 (en) * 1997-11-07 1999-05-20 Daiichi Pharmaceutical Co. Ltd. Piperazine-cyclodextrin complexes
EP1067942A1 (en) * 1998-02-23 2001-01-17 Cyclops, EHF. High-energy cyclodextrin complexes
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
WO2000033885A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
CZ20012601A3 (cs) 1999-01-21 2002-05-15 Bristol-Myers Squibb Company Komplex inhibitoru ras-farnesyltranferasy a sulfobutylether-7beta-cyklodextrinu nebo 2-hydroxypropyl-beta-cyklodextrinu a způsob
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
WO2001030391A2 (en) * 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
EP1267941B1 (en) * 2000-03-28 2005-11-23 Farmarc Nederland B.V. Alprazolam inclusion complexes and pharmaceutical compositions thereof
ATE416791T1 (de) * 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
ME00555B (me) 2000-05-26 2011-12-20 Pfizer Derivati tropana i njihova primj ena
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
AR030312A1 (es) * 2000-08-03 2003-08-20 Antares Pharma Ipl Ag Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
EP1425311A4 (en) * 2001-01-11 2004-12-01 Eastman Chem Co CYCLODEXTRINSULFONATES, GUEST INCLUDING COMPLEXES, METHOD FOR THEIR PRODUCTION AND RELATED MATERIALS
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ES2283532T3 (es) 2001-04-10 2007-11-01 Pfizer, Inc. Derivados de pirazol para tratar el vih.
UA75135C2 (en) * 2001-05-01 2006-03-15 Pfizer Prod Inc Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7008934B2 (en) * 2001-06-28 2006-03-07 Baxter International Inc. Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
EP1414498A2 (en) * 2001-06-29 2004-05-06 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
US20040198698A1 (en) * 2001-07-20 2004-10-07 Walter Heinzelmann Nitrate ester-cyclodextrin complexes
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
CA2475712C (en) 2002-02-11 2009-11-24 Simon Bailey Nicotinamide derivatives useful as pde4 inhibitors
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
AU2003213210A1 (en) * 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
RU2220711C1 (ru) * 2002-04-24 2004-01-10 Закрытое акционерное общество "Брынцалов-А" Противомикробное и противопротозойное средство "трихоброл"
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
EP1542668B1 (en) * 2002-08-20 2009-04-15 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
RU2220739C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Интраназальное средство
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
RU2359698C2 (ru) * 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2513320C (en) * 2003-01-14 2018-03-27 Yeda Research And Development Co. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
MXPA05007552A (es) 2003-01-14 2006-05-19 Teva Pharma Formulaciones parenterales de un peptido para el tratamiento de lupus sistemico eritematoso.
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
WO2004091630A1 (ja) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute 眼に適用する疾患治療剤
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EA009457B1 (ru) 2003-09-03 2007-12-28 Пфайзер Инк. Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
EP1663398B1 (en) 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
GEP20084417B (en) 2003-10-03 2008-07-10 Pfizer Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
BRPI0416812A (pt) 2003-11-21 2007-03-06 Combinatorx Inc métodos e reagentes para o tratamento de desordens inflamatórias
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
HUE032527T2 (en) * 2003-12-31 2017-09-28 Cydex Pharmaceuticals Inc Sulphoalkyl ether cyclodextrin and corticosteroid inhalation preparation
DE602005001929T2 (de) 2004-01-22 2007-12-06 Pfizer Inc. Sulfonamidderivate zur behandlung von krankheiten
AP2359A (en) 2004-01-22 2012-01-30 Pfizer Sulfonamide derivatives for the treatment of diseases.
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
CA2560510C (en) 2004-03-18 2009-10-13 Pfizer Inc. N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
MXPA06012240A (es) * 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
ES2510840T3 (es) * 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MX2007001759A (es) 2004-08-12 2007-04-20 Pfizer Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos.
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
EP1809607B1 (en) 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
DE602005026556D1 (de) * 2004-12-07 2011-04-07 Proteolix Inc Zusammensetzung zur proteasomhemmung
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
KR101332869B1 (ko) * 2005-04-15 2013-11-25 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 항-ｅｇｆｒ 치료법에 속발된 피부 발진의 예방 및 치료를위한 비타민 ｋ
ES2525096T3 (es) 2005-04-19 2014-12-17 Kings College London Uso de bip contra la pérdida ósea y osteoporosis
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
CA2612287C (en) 2005-06-15 2011-01-25 Pfizer Limited Substituted arylpyrazoles for use against parasites
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
EP1928464B1 (en) 2005-09-30 2014-05-14 Lundbeck Inc. Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
LT2952197T (lt) * 2005-10-26 2017-08-25 Cydex Pharmaceuticals, Inc. Sulfonalkileterio ciklodekstrino kompozicijos ir jų gavimo būdai
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
EP1971347A2 (en) * 2005-12-20 2008-09-24 Tika Läkemedel AB Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
CA2642641A1 (en) * 2006-02-15 2007-08-23 Tika Laekemedel Ab Stable corticosteroid mixtures
TW200806298A (en) * 2006-03-24 2008-02-01 Wyeth Corp Methods for modulating bladder function
MX2008012208A (es) * 2006-03-24 2008-10-02 Wyeth Corp Metodo para tratar trastornos cognitivos y otros afines.
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
US20070225334A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
CA2650922C (en) * 2006-04-18 2015-09-29 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
CN100374468C (zh) * 2006-05-25 2008-03-12 重庆通量精细化工有限公司 水溶性磺烷基醚-β-环糊精的合成工艺
MY183014A (en) * 2006-06-19 2021-02-05 Onyx Therapeutics Inc Compounds for enzyme inhibition
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
US20080207731A1 (en) 2006-08-23 2008-08-28 Intellect Neurosciences, Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
WO2008031439A2 (en) 2006-09-15 2008-03-20 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
PT2061458E (pt) * 2006-09-15 2015-03-11 Univ Minnesota Composições de topiramato e métodos para a sua utilização
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
MX2009000080A (es) 2006-09-21 2009-01-23 Raqualia Pharma Inc Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
WO2008045563A2 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
RS51647B (sr) 2006-10-18 2011-10-31 Pfizer Products Inc. Jedinjenja biaril etar uree
BRPI0717460A2 (pt) 2006-10-20 2013-12-24 Icos Corp Composições de inibidores de chk1
CA2666539A1 (en) 2006-10-23 2008-05-02 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
WO2008106721A1 (en) * 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
CA2685331C (en) * 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
AU2015255164B2 (en) * 2007-04-27 2017-06-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
US8563000B2 (en) 2007-05-25 2013-10-22 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
EP2215087B1 (en) 2007-09-05 2013-12-18 Rigel Pharmaceuticals, Inc. Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
KR100929920B1 (ko) * 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
KR20150131405A (ko) * 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303229A1 (en) * 2008-06-16 2011-04-06 Debiopharm S.A. Concentrated oxaliplatin solution and its method of preparation
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
EP2328890B1 (en) 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CN104958296B (zh) 2008-11-15 2017-12-01 麦林塔医疗有限公司 抗微生物组合物
JP5621148B2 (ja) 2008-11-21 2014-11-05 ラクオリア創薬株式会社 ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
US20120027722A1 (en) 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
NZ593473A (en) 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
TWI453029B (zh) 2009-01-14 2014-09-21 Novacta Biosystems Ltd 去氧艾克特卡丁b(deoxyactagardine b), 包含其之醫藥組合物及其製造方法
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR20190071006A (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
JP2012528140A (ja) 2009-05-29 2012-11-12 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
MX388477B (es) 2009-05-29 2025-03-12 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
NZ601267A (en) 2009-12-23 2014-03-28 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
AU2011207103B2 (en) 2010-01-21 2013-03-21 Drawbridge Pharmaceuticals Pty Ltd Anaesthetic formulation
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2531519A1 (en) 2010-02-02 2012-12-12 Novacta Biosystems Limited Lantibiotic salts
JP2013520489A (ja) 2010-02-25 2013-06-06 ファイザー・リミテッド ペプチド類似体
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011228758A1 (en) * 2010-03-13 2012-11-08 Eastpond Laboratories Limited Fat-binding compositions
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
CA2837129C (en) 2010-05-26 2018-07-03 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
EP2579869A2 (en) * 2010-06-11 2013-04-17 Baxter International Inc Formulations including amiodarone and salts thereof and methods of their manufacture and use
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
BR112013004275A2 (pt) 2010-08-24 2016-08-02 Imp Innovations Ltd glicodendrímeros de polipropileterimina
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
MX343274B (es) 2010-11-15 2016-10-31 Viiv Healthcare Uk Ltd Inhibidores de la replicacion del vih.
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
ES2672238T3 (es) 2011-01-26 2018-06-13 Allergan, Inc. Composición androgénica para el tratamiento de una afección oftálmica
WO2012148548A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
MX2013011612A (es) 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
MX350024B (es) 2011-05-18 2017-08-23 Raqualia Pharma Inc Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
KR101731155B1 (ko) 2011-06-15 2017-04-27 신톤 비.브이. 안정화된 보리코나졸 조성물
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2731959B1 (en) 2011-07-13 2016-02-03 Pfizer Limited Enkephalin analogues
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2739274A1 (en) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Treatment of cognitive impairment
BR112014002141A2 (pt) 2011-08-02 2017-02-21 Pfizer crizotinib para uso no tratamento de câncer
RS64332B1 (sr) 2011-09-08 2023-08-31 Sage Therapeutics Inc Neuroaktivni steroidi, kompozicije i njihova upotreba
CA2847842C (en) 2011-09-18 2019-12-31 Euro-Celtique S.A. Pharmaceutical compositions
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JP6067031B2 (ja) 2012-01-04 2017-01-25 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アミノスルホニルベンズアミド
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
EP4083075A1 (en) 2012-02-15 2022-11-02 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
WO2013130666A1 (en) 2012-02-28 2013-09-06 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
EP2822953B9 (en) 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CN104302673B (zh) 2012-03-30 2017-09-22 赛博尔泰克股份公司 花青素复合物
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
JP2015524444A (ja) 2012-08-03 2015-08-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ライソゾーム蓄積症を治療するためのシクロデキストリン
WO2014039831A1 (en) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
EP2897950A1 (en) 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014053965A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
WO2014060548A1 (de) * 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin-komplex zur behandlung von multiplem myelom
MX360192B (es) 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
BR112015010620A2 (pt) 2012-11-08 2017-07-11 Pfizer compostos heteroaromáticos e seus usos como ligantes de dopamina d1
SG11201502884TA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds as dopamine d1 ligands
US9925274B2 (en) * 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
HK1208457A1 (en) 2012-11-21 2016-03-04 拉夸里亚创药株式会社 Polymorph forms
WO2014087298A1 (en) 2012-12-03 2014-06-12 Pfizer Inc. Novel selective androgen receptor modulators
HK1215392A1 (zh) * 2012-12-11 2016-08-26 赛博尔泰克股份公司 用於对抗黑色素瘤细胞的飞燕草素
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2948149B1 (en) 2013-01-23 2026-03-04 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
PT3431475T (pt) 2013-02-21 2021-05-13 Pfizer Formas sólidas de um inibidor de cdk4/6 seletivo
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
WO2014160441A1 (en) 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3461834T3 (da) 2013-03-13 2021-08-23 Sage Therapeutics Inc Neuroaktive steroider
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
HRP20190232T1 (hr) 2013-04-17 2019-03-22 Sage Therapeutics, Inc. 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
DK3013813T3 (da) 2013-06-27 2019-06-03 Pfizer Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
CN105517541A (zh) 2013-07-08 2016-04-20 艾伯维公司 包含阿曲生坦的稳定化药物剂型
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI3488852T1 (sl) 2013-08-23 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RU2572334C2 (ru) * 2013-12-06 2016-01-10 Общество С Ограниченной Ответственностью "Луфатен" Клатратный комплекс арабиногалактана или гуммиарабика с 20-гидроксиэкдизоном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
US9371321B2 (en) 2014-01-09 2016-06-21 Astrazeneca Ab Azaindole derivatives
CN104971355B (zh) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
PE20170008A1 (es) 2014-04-25 2017-03-17 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
TN2016000447A1 (en) 2014-04-25 2018-04-04 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands.
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
AU2015260905A1 (en) 2014-05-14 2016-12-01 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
PL3143019T3 (pl) 2014-05-15 2021-03-22 Pfizer Inc. Krystaliczna postać 6-[(4R)-4-metylo-1,2-dioksydo-1,2,6-tiadiazynan-2-ylo]izochinolino-1-karbonitrylu
EP3145926B1 (en) 2014-05-20 2019-07-03 RaQualia Pharma Inc. Benzisoxazole derivative salt
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
KR102494061B1 (ko) 2014-05-29 2023-01-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
MD4820C1 (ro) 2014-06-17 2023-03-31 Pfizer Inc. Compuşi dihidroizochinolinonici substituiţi
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
NZ725354A (en) 2014-06-18 2018-05-25 Elanco Us Inc Transdermal formulations of pergolide and uses thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
JP6914188B2 (ja) * 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
KR20170065637A (ko) 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. 신경활성 화합물 및 그의 사용 방법
SG11201703073UA (en) 2014-10-16 2017-05-30 Sage Therapeutics Inc Compositions and methods for treating cns disorders
PT3206493T (pt) 2014-10-16 2020-08-03 Sage Therapeutics Inc Composições e métodos para tratamento de transtornos do snc
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
UY36530A (es) 2015-01-22 2016-08-31 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies
US20160228454A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
ES2792899T3 (es) 2015-02-24 2020-11-12 Pfizer Derivados de nucleósidos sustituidos útiles como agentes anticancerosos
CA2979527A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
JP6971963B2 (ja) 2015-03-19 2021-11-24 サイデックス・ファーマシューティカルズ・インコーポレイテッド シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
MD3319612T2 (ro) 2015-07-06 2021-10-31 Sage Therapeutics Inc Oxisteroli și metode de utilizare a acestora
KR102703602B1 (ko) 2015-07-06 2024-09-06 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
WO2017007805A1 (en) 2015-07-09 2017-01-12 Gilead Sciences, Inc. Intravenous formulations of a late sodium current inhibitor
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017098367A1 (en) 2015-12-10 2017-06-15 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
EA039213B1 (ru) 2015-12-24 2021-12-17 Такеда Фармасьютикал Компани Лимитед Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
SG11201805202VA (en) 2016-01-15 2018-07-30 Pfizer 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
HUE069322T2 (hu) 2016-02-18 2025-03-28 Melinta Therapeutics Llc Oritavancin készítmények
MX2018010292A (es) 2016-02-28 2018-09-27 Aldeyra Therapeutics Inc Tratamiento de condiciones oculares alergicas con ciclodextrinas.
EP3426772A4 (en) 2016-03-09 2019-08-28 Beijing Percans Oncology Co. Ltd. TUMOR CELLSUSPENSION CULTURES AND RELATED METHODS
PL3436447T3 (pl) * 2016-03-31 2021-12-27 Takeda Pharmaceutical Company Limited Kompleksy triazolonu izochinolinylowego
HRP20220716T1 (hr) 2016-04-01 2022-09-02 Sage Therapeutics, Inc. Oksisteroli i postupci za njihovu uporabu
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
RS62222B1 (sr) 2016-07-07 2021-09-30 Sage Therapeutics Inc 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
IL264129B2 (en) 2016-07-11 2024-05-01 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
US20190270778A1 (en) 2016-07-29 2019-09-05 Pfizer Inc. Cyclic Peptides As C5a Receptor Antagonists
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
KR20250054838A (ko) 2016-10-18 2025-04-23 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
KR102583278B1 (ko) 2016-10-18 2023-09-27 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
AU2017361875A1 (en) 2016-11-18 2019-06-06 Aicuris Gmbh & Co. Kg Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
CA3047729A1 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
EP3558950B1 (en) 2016-12-20 2023-05-10 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
ES2864405T3 (es) 2017-01-20 2021-10-13 Shenzhen Targetrx Inc Compuesto de (hetero)arilamida para inhibir la actividad de proteína quinasa
WO2018133826A1 (zh) 2017-01-20 2018-07-26 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
SG11201906417RA (en) 2017-01-20 2019-08-27 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201906427QA (en) 2017-01-23 2019-08-27 Pfizer Heterocyclic spiro compounds as magl inhibitors
WO2018146698A1 (en) 2017-02-07 2018-08-16 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
JP7175026B2 (ja) 2017-04-01 2022-11-18 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン系化合物
MX2019013053A (es) 2017-05-03 2020-02-07 Cydex Pharmaceuticals Inc Composicion que contiene ciclodextrina y busulfan.
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
JP7296954B2 (ja) 2017-06-22 2023-06-23 キュラデブ・ファーマ・リミテッド ヒトｓｔｉｎｇの小分子調節因子
EP3626241B1 (en) 2017-06-26 2025-04-23 Shenzhen TargetRx, Inc. Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
EP3626709A4 (en) 2017-06-26 2020-03-25 Shenzhen Targetrx, Inc. INDAZOLIC COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF
ES3000461T3 (en) 2017-07-11 2025-02-28 Gilead Sciences Inc Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
EP3666774B1 (en) 2017-08-11 2022-05-11 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor
KR102782200B1 (ko) 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
WO2019042187A1 (zh) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CA3074885A1 (en) 2017-09-05 2019-03-14 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
CN111201223B (zh) 2017-09-11 2024-07-09 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US20210228596A1 (en) 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
WO2019120094A1 (zh) 2017-12-21 2019-06-27 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的芳基磷氧化物
CN118388536A (zh) 2017-12-21 2024-07-26 深圳市塔吉瑞生物医药有限公司 用于抗病毒的新型核苷类逆转录酶抑制剂
US11254696B2 (en) 2017-12-21 2022-02-22 Shenzhen Targetrx, Inc. Dianilinopyrimidine compound for inhibiting kinase activity
EP3730503B8 (en) 2017-12-21 2026-03-18 Shenzhen TargetRx Co., Ltd. Antiviral nucleoside reverse transcriptase inhibitor
MX2020006599A (es) 2017-12-22 2020-11-06 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
EP3746419A1 (en) 2018-01-29 2020-12-09 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
TWI741268B (zh) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
US11459334B2 (en) 2018-04-16 2022-10-04 Shenzhen Targetrx, Inc. Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
EP3770161B1 (en) 2018-04-16 2022-08-24 Shenzhen TargetRx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
HUE070823T2 (hu) 2018-04-26 2025-07-28 Pfizer 2-amino-piridin- vagy 2-amino-pirimidin-származékok ciklinfüggõ kináz gátlószereiként
EP3801481A1 (en) 2018-05-30 2021-04-14 Convert Pharmaceuticals SA Prodrugs and medical uses thereof
WO2019232201A1 (en) 2018-06-01 2019-12-05 Bayer Cropscience Lp Stabilized fungicidal composition comprising cyclodextrin
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
JP7162372B2 (ja) 2018-07-02 2022-10-28 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのアルキニル（ヘテロ）芳香族化合物
JP7262843B2 (ja) 2018-07-12 2023-04-24 深▲チェン▼市塔吉瑞生物医薬有限公司 ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
EP3808746B1 (en) 2018-07-17 2023-08-02 Shenzhen TargetRx, Inc. N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
AU2019304198A1 (en) 2018-07-19 2021-02-04 Pfizer Inc. Heterocyclic spiro compounds as MAGL inhibitors
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CA3113462A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations of reproxalap for the treatment of dry eye disease
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
EP3845538B1 (en) 2018-10-10 2023-11-08 Shenzhen TargetRx, Inc. Dihydroimidazopyrazinone compound, composition including same, and use thereof
ES2966055T3 (es) 2018-10-12 2024-04-18 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC
TW202027754A (zh) 2018-10-19 2020-08-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
TWI736037B (zh) 2018-11-29 2021-08-11 美商輝瑞股份有限公司 化學化合物
TW202521129A (zh) 2018-12-05 2025-06-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
EP3878852A4 (en) 2018-12-06 2021-12-15 Shenzhen TargetRx, Inc. SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUND, COMPOSITION THEREOF, AND USE THEREOF
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12377076B2 (en) 2018-12-18 2025-08-05 Purdue Pharma L.P. Compounds for treating lymphoma or a T-cell malignant disease
CA3124371A1 (en) 2018-12-21 2020-06-25 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
WO2020125391A1 (zh) 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
WO2020141226A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CN113271923B (zh) 2019-01-04 2025-05-13 Sq创新股份公司 呋塞米的药物组合物及其用途
CA3124703C (en) 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
US20210387992A1 (en) 2019-01-23 2021-12-16 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
EP3917913A2 (en) 2019-01-31 2021-12-08 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
US12365685B2 (en) 2019-02-18 2025-07-22 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
JP7241435B2 (ja) 2019-02-27 2023-03-17 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾール系化合物および該当化合物を含む組成物並びにその使用
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
CN113993585B (zh) 2019-03-27 2024-10-01 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
SG11202111717XA (en) 2019-04-29 2021-11-29 Solent Therapeutics Llc 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
BR112021026447A2 (pt) 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
KR20220038680A (ko) 2019-06-27 2022-03-29 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021014415A2 (en) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
WO2021026310A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
JP7593998B2 (ja) 2019-08-23 2024-12-03 北京泰徳製薬股▲フン▼有限公司 Ｅｇｆｒおよびａｌｋを阻害してそれらの分解を阻害する化合物
AR119971A1 (es) 2019-09-16 2022-01-26 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
KR20220070254A (ko) 2019-09-25 2022-05-30 화이자 인코포레이티드 Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
AU2020355359B2 (en) 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
EP4056570B1 (en) 2019-11-01 2026-01-07 ShanghaiTech University Eed inhibitor, and preparation method therefor and use thereof
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US12410192B2 (en) 2019-12-16 2025-09-09 Beijing Tide Pharmaceutical Co., Ltd. Compound for inhibiting and inducing degradation of EGFR kinase
CN119080674A (zh) 2020-01-17 2024-12-06 晟科药业（江苏）有限公司 作为pcsk9抑制剂的化合物
CN115151304B (zh) 2020-02-12 2025-02-11 库拉德夫制药私人有限公司 小分子干扰素基因刺激因子(sting)拮抗剂
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
CN115515933A (zh) 2020-05-04 2022-12-23 武田药品工业株式会社 经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
KR102880549B1 (ko) 2020-05-20 2025-11-04 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물
WO2021262836A1 (en) 2020-06-24 2021-12-30 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US11292765B2 (en) 2020-06-30 2022-04-05 Field Trip Psychedelics Inc. Tryptamine prodrugs
BR112023000654A2 (pt) 2020-07-13 2023-04-25 Beijing Tide Pharmaceutical Co Ltd Composto de pirazolopirimidina usado como inibidor de atr quinase
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
JP7721167B2 (ja) 2020-08-27 2025-08-12 晟科薬業（江蘇）有限公司 新規な選択的ｆｌｔ３阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン化合物
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
CA3195121A1 (en) 2020-10-09 2022-04-14 Robert A. Volkmann Heteroaryl amide inhibitors of cd38
KR20230124916A (ko) 2020-11-25 2023-08-28 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
EP4313151A1 (en) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
CN117545751A (zh) 2021-04-07 2024-02-09 生命爱科 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
KR20240027048A (ko) 2021-06-26 2024-02-29 어레이 바이오파마 인크. Her2 돌연변이 억제제
KR20240037975A (ko) 2021-07-28 2024-03-22 세이지 테라퓨틱스, 인크. 신경활성 스테로이드의 결정질 형태
AU2022325543A1 (en) 2021-08-11 2024-02-15 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
TW202321231A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 作為sting拮抗劑之小分子尿素衍生物
US20240417423A1 (en) 2021-09-22 2024-12-19 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
FI4441052T3 (fi) 2021-12-01 2026-02-17 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Yhdisteitä
KR20240134949A (ko) 2022-01-17 2024-09-10 수조우 푸허 바이오파마 컴퍼니 리미티드 Egfr 억제제 역할을 하는 2-피페리딜 또는 2-피라졸릴 치환된 피리미딘 화합물
WO2023144692A1 (en) * 2022-01-25 2023-08-03 Leiutis Pharmaceuticals Llp Novel naproxen sodium preparations for parenteral
CA3244449A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Hydroxypropyl-beta-cyclodextrin compositions and related purification methods
EP4474377A4 (en) 2022-03-03 2025-07-30 Shenzhen Targetrx Inc Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
CA3255222A1 (en) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
US20250257086A1 (en) 2022-04-15 2025-08-14 Beijing Tide Pharmaceutical Co., Ltd. Egfr degradation agent
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
EP4332087A1 (en) 2022-04-29 2024-03-06 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticles
CN116969851A (zh) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
JP2025525104A (ja) 2022-07-28 2025-08-01 ベイジン アースワイズ テクノロジー カンパニー リミテッド Ｐｒｍｔ５阻害剤
CA3263179A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors
AR130151A1 (es) 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
IL320683A (en) 2022-11-15 2025-07-01 Curadev Pharma Ltd Pyridone and pyrimidinone inhibitors of hematopoietic progenitor cell kinase 1
CN120882732A (zh) 2022-11-21 2025-10-31 萨奇治疗股份有限公司 负nmda调节化合物和其使用方法
WO2024120464A1 (zh) 2022-12-09 2024-06-13 深圳市塔吉瑞生物医药有限公司 核苷酸类似物及其组合物及用途
CN120322435A (zh) 2022-12-23 2025-07-15 浙江扬厉医药技术有限公司 Parp1抑制剂
WO2024140923A1 (zh) 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
JP2026502971A (ja) 2022-12-30 2026-01-27 蘇州浦合医薬科技有限公司 Ｗｒｎ阻害剤
PE20252398A1 (es) 2023-01-17 2025-10-10 Suzhou Puhe Biopharma Co Ltd Inhibidores de prmt5-mta
WO2024153216A1 (zh) 2023-01-20 2024-07-25 北京泰德制药股份有限公司 蛋白靶向降解的嵌合体化合物
EP4655303A1 (en) 2023-01-26 2025-12-03 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
AU2024255473A1 (en) 2023-04-14 2025-10-16 Takeda Pharmaceutical Company Limited Pyrazolopyrimidine derivatives as inhibitors of nlrp3
WO2024229297A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Lymphatic system-targeting compounds
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer
KR20260020180A (ko) 2023-06-06 2026-02-10 후아 메디슨 (상하이) 엘티디. 인지 장애 및 신경퇴행성 질병을 위한 글루코키나아제 활성제
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025007863A1 (zh) 2023-07-03 2025-01-09 深圳市塔吉瑞生物医药有限公司 1H-吡唑并[4,3-c]吡啶化合物及其组合物及用途
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025221732A1 (en) 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof
WO2025221731A1 (en) 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025250816A1 (en) 2024-05-29 2025-12-04 Sage Therapeutics, Inc. Agents for delivering nmda receptor modulating compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (es) * 1970-06-10 1975-02-04
NZ199543A (en) * 1981-01-23 1985-04-30 Wellcome Found Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications

Also Published As

Publication number Publication date
WO1994002518A1 (en) 1994-02-03
EP0620828B2 (en) 2008-07-09
AU4779993A (en) 1994-02-14
GEP19991649B (en) 1999-06-14
PT620828E (pt) 2002-10-31
DE69331900D1 (de) 2002-06-13
DK0620828T4 (da) 2008-11-03
ATE217325T1 (de) 2002-05-15
DK0620828T3 (da) 2002-08-26
DE69331900T3 (de) 2009-03-26
TJ275B (en) 2000-10-05
RU2113442C1 (ru) 1998-06-20
EP0620828A4 (en) 1996-05-15
MD1813B2 (en) 2001-12-31
EP0620828B1 (en) 2002-05-08
ES2176206T5 (es) 2008-12-01
KR100279111B1 (ko) 2001-03-02
CA2119154C (en) 1998-06-16
CA2119154A1 (en) 1994-02-03
JPH06511513A (ja) 1994-12-22
JP3393253B2 (ja) 2003-04-07
DE69331900T2 (de) 2003-01-16
EP0620828A1 (en) 1994-10-26
US5376645A (en) 1994-12-27
MD1813C2 (ro) 2002-08-31
AU672814B2 (en) 1996-10-17

Similar Documents

Publication Publication Date Title
ES2176206T3 (es) Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos.
ATE170742T1 (de) Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung
ES2081397T3 (es) O-metil derivados de azitromicina a, procedimiento y productos intermedios para su preparacion, y uso de los mismos en la preparacion de productos farmaceuticos.
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ES2086643T3 (es) Derivados de camptotecina solubles en agua.
ES2058503T3 (es) Formulaciones farmaceuticas para uso parenteral.
AR007960A1 (es) Nuevos derivados de imino, procedimiento para su preparacion, preparado farmaceutico que los contiene y su utilizacion
ES2086371T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
NL300136I1 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FI931503A7 (fi) Indolijohdannaisia allergian ja tulehduksen vastaisina aineina
LU91289I2 (fr) Testostérone en combinaison avec du pentadécalactone et ses dérivés pharmaceutiquement acceptables -TESTIM
GR880100602A (el) Υδατοδιαλυτοι μονοεστερες ως διαλυτοποιητες για φαρμακολογικως δραστικες ενωσεις και φαρμακευτικα εκδοχα
ES2118955T3 (es) Derivados de dolastatina.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2084740T3 (es) Derivados de diamino-5-triazinona y composiciones polimericas autoextinguentes que los contienen.
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9400215A (es) Compuestos farmaceuticos.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.